Acta Med. 2012, 55: 116-124

Antiproliferative Effects of Selected Chemotherapeutics in Human Ovarian Cancer Cell Line A2780

Kateřina Caltová, Miroslav Červinka

Charles University in Prague, Faculty of Medicine in Hradec Králové, Czech Republic: Department of Medical Biology and Genetics

Received June 14, 2012
Accepted August 22, 2012


1. Basu A, Haldar S. The relationship between bcl-2, bax and p53: Consequences for cell cycle progression and cell death. Mol Hum Reprod 1998; 4: 1099–1109. <>
2. Behrens BC, Grotzinger KR, Hamilton TC et al. Cytotoxicity of 3 cisplatin (CP) analogues in a drug-sensitive and a new CP resistant human ovarian cancer (OC) cell line. Proc. Am. Assoc. Cancer Res. 1985; 26: 262.
3. Bharadwaj R, Yu H. The spindle checkpoint, aneuploidy, and cancer. Oncogene 2004; 23(11): 2016–27. <>
4. Bolis G, Scarfone G, Polverino G et al. Paclitaxel 175 or 225 mg per meters squared with carboplatin in advanced ovarian cancer: a randomized trial. J Clin Oncol 2004; 22: 686–690. <>
5. Brigulová K, Červinka M, Tošner J et al. Chemoresistance testing of human ovarian cancer cells and its in vitro model. Toxicol in vitro 2010; 24: 2108–15. <>
6. Brito DA, Yang Z, Rieder CL. Microtubules do not promote mitotic slippage when the spindle assembly checkpoint cannot be satisfied. The Journal of Cell Biology 2008; 182(4): 623–9. <> <PubMed>
7. Chobanian N, Dietrich CS. Ovarian cancer. Surg. Clin. North Am. 2008; 88(2): 285–99. <>
8. Cibula D, Petruželka L et al. Oncogynecology. Prague, Grada Publishing 2009: 614.
9. Conklin KA. Cancer chemotherapy and antioxidants. J. Nutr. 2004; vol. 134 no. 11.
10. Creemers GJ, Bolis G, Gore M et al. Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study. J Clin Oncol 1996; 14: 3056–61. <>
11. Debernardis D, Siré EG, Feudis P et al. p53 status does not affect sensitivity of human ovarian cancer cell lines to paclitaxel. Cancer Res 1997; 57: 870.
12. Deng C, Zhang P, Harper JW et al. Mice lacking p21CIP1/WAF 1 undergo normal development, but are defective in G1 checkpoint control. Cell 1995; 82: 675–684. <>
13. Denizot F, Lang R. Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. J Immunol Methods 1986; 89: 271–7. <>
14. Deveraux QL, Reed JC. IAP family proteins – suppressors of apoptosis. Genes Dev. 1999; 13(3): 239–52. <>
15. Dulic V, Kaufman WK, Wilson SJ et al. p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest. Cell 1994; 76: 1013–1023. <>
16. Essers J, Theil AF, Baldeyron C et al. Nuclear dynamics of PCNA in DNA replication and repair. Mol. Cell. Biol. 2005; 25(21): 9350–9359. <> <PubMed>
17. Flick MB, O’Malley D, Rutherford T et al. Apoptosis-Based Evaluation of Chemosensitivity in Ovarian Cancer Patients. Reproductive Sciences. 2004; 11(4): 252–259.
18. Godwin AK, Meister A, O’Dwyer PJ et al. High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc. Natl. Acad. Sci. USA 1992; 89: 3070–74. <> <PubMed>
19. Gordaliza M, García PA, Corral JM et al. Podophyllotoxin: distribution, sources, applications and new cytotoxic derivatives. Toxicon 2004; 44(4): 441–59. <>
20. Gore ME, Fryatt I, Wiltshaw E et al. Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds. Gynecol Oncol 1990; 36: 207–11. <>
21. Henkels KM, Turchi JJ. Induction of apoptosis in cisplatin-sensitive and –resistant human ovarian cancer cell lines. Cancer Research 1997; 57: 4488–92.
22. Johnson DG., Walker CL. Cyclins and cell cycle checkpoints. Annu. Rev. Pharmacol. Toxicol. 1999; 39: 295–312. <>
23. Jones NA, Turner J, McIlwrath AJ et al. Cisplatin- and Paclitaxel-Induced Apoptosis of Ovarian Carcinoma Cells and the Relationship between Bax and Bak Up-Regulation and the Functional Status of p53. Molecular Pharmacology 1998; (53)5: 819–26.
24. Kalábová R. Docetaxel - the use in the treatment of advanced and relapsing ovarian cancer. Gynekolog 2005; 1: 6–8.
25. Kelman Z, O’Donnell M. Structural and functional similaritites of prokaryotic and eukaryotic DNA polymerase sliding clamps. Nucleic Acids Res. 1995; 23: 3613–20. <> <PubMed>
26. Kudelka AP, Tresukosol D, Edwards CL et al. Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma. J Clin Oncol 1996; 14: 1552–57. <>
27. Ludwig T, Oberleithner H. Platinum complex toxicity in cultured renal epithelia. Cell Physiol Biochem 2004; 14: 431–40. <>
28. Ludwig T, Riethmüller Ch, Gekle M et al. Nephrotoxicity of platinum complexes is related to basolateral organic cation transport. Kidney International 2004; 66: 196–202. <>
29. Markman M, Rothman R, Hakes T et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 1991; 9: 389–93. <>
30. Ozols RF et al. Contemporary issues in the management of ovarian cancer. Sem Oncol 2000; 27(suppl 7): 1–2.
31. Plunkett W, Huang P, Xu YZ et al. Gemcitabine: metabolism, mechanisms of action, and self-potentiation. Semin Oncol. 1995; 22(4 Suppl 11): 3–10.
32. Roche Diagnostics GmbH. xCELLigence System, Application Note No. 1. Realtime and Dynamic Monitoring of Cell Proliferation and Viability for Adherent Cells. 2008. (Accessed at /sct_Excelligence_2009//excellig1.pdf.)
33. Shivji KK, Kenny MK, Wood RD. Proliferating cell nuclear antigen is required for DNA excision repair. Cell 1992; 69(2): 367–74. <>
34. Slee EA , Adrain C, Martin SJ. Executioner caspase 3, -6, and -7 perform distinct, non-redundant roles during the demolition phase of apoptosis. J Biol Chem 2001; 276: 7320–26. <>
35. Staker BL, Hjerrild K, Feese MD et al. The mechanism of topoisomerase I poisoning by a camptothecin analog. PNAS 2002; 99(24): 15387–92. <> <PubMed>
36. Swisher EM, Mutch DG , Rader JS et al. Topotecan in platinum- and paclitaxel- resistant ovarian cancer. Gynecol Oncol 1997; 66: 480–86. <>
37. Vigo E, Müller H, Prosperini E et al. CDC25A phosphatase is a target of E2F and is required for efficient E2F-induced S phase. Mol Cell Biol 1999; 19(9): 6379–95. <>
38. Vikhanskayaa F, Vignatia S, Beccagliaa P et al. Inactivation of p53 in a Human Ovarian Cancer Cell Line Increases the Sensitivity to Paclitaxel by Inducing G2/M Arrest and Apoptosis. Experimental Cell Research 1998; 241(1): 96–101. <>
front cover

ISSN 1211-4286 (Print) ISSN 1805-9694 (Online)

Open access journal